Keith Wonnacott

Keith Wonnacott is the Vice President of Regulatory Affairs at LEXEO Therapeutics, a biotechnology company focused on gene therapy.1 He is an experienced professional in the field of gene therapy and regulatory affairs, with a strong background in the pharmaceutical and biotechnology industries.

Professional Experience

Keith Wonnacott's career at LEXEO Therapeutics involves leading regulatory strategies for gene therapy products. His role likely includes:

• Overseeing regulatory submissions and interactions with regulatory agencies
• Developing global regulatory strategies for gene therapy products
• Ensuring compliance with regulatory requirements in various markets

Expertise and Interests

Keith demonstrates a keen interest and expertise in:

• Gene therapy: He is actively involved in the gene therapy field, particularly for rare disorders.3
• Regulatory affairs: His position focuses on navigating the complex regulatory landscape for advanced therapies.12
• Biotechnology: He identifies as a biotechnology professional and cell and gene therapy enthusiast.4

Professional Activities

Keith Wonnacott is engaged in various professional activities that showcase his expertise:

• Speaking engagements: He was scheduled to speak at the 7th Gene Therapy for Rare Disorders Summit in Boston, MA, in March 2024.3
• Recruitment: He has been involved in recruiting for his team, seeking experienced Global Regulatory Leads.2
• Industry discussions: He contributes to discussions about regulatory challenges in gene therapy, such as genetically modified organism requirements.4

Networking and Influence

Keith maintains an active professional presence:

• He has over 500 connections on LinkedIn, indicating a strong professional network in his field.1
• His LinkedIn profile serves as a platform for sharing industry insights and career opportunities in gene therapy and regulatory affairs.

Keith Wonnacott's role at LEXEO Therapeutics and his involvement in the gene therapy field position him as a key figure in navigating the regulatory landscape for advanced therapeutic products, particularly in the treatment of rare disorders.